logo

For the Inventor, By the Inventor

Gauting, Germany

Matthias Habjan

This inventor holds 4 USPTO granted patents and 3 published patent applications. Top assignee: Bavarian Nordic A/s. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Habjan. Retrieved from https://idiyas.com/inventor/matthias-habjan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0

Average Co-Inventor Count = 4.6

ph-index = 1


Location History:

  • Gauting, DE (2022)
  • Puchheim, DE (2023)

Company Filing History:

goldMedal4 out of 136 
 
Bavarian Nordic A/s
 patents

Years Active: 2022-2026

Loading Chart...
4 patents (USPTO):Explore Patents
1. 12758628 - Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer (2026-10-13),
2. 12746282 - A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease (2026-09-29),
3. 11723964 - Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA (2023-08-15),
4. 11273211 - Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody (2022-03-15),

Title: Matthias Habjan: Innovator in Cancer Treatment

Introduction

Matthias Habjan is a prominent inventor based in Gauting, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical combinations. With a total of 4 patents, his work focuses on improving the survival rates of cancer patients.

Latest Patents

Habjan's latest patents include groundbreaking inventions aimed at treating cancer. The first patent, titled "Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA," relates to a pharmaceutical combination designed to reduce tumor volume and increase the survival of cancer patients. This combination involves the intravenous administration of a recombinant MVA encoding a tumor-associated antigen alongside an antibody treatment. The second patent, "Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody," echoes similar themes, emphasizing the importance of this innovative approach in cancer therapy.

Career Highlights

Matthias Habjan is associated with Bavarian Nordic A/S, a company known for its focus on developing innovative cancer therapies. His work at the company has positioned him as a key player in the pharmaceutical industry, particularly in the realm of oncology.

Collaborations

Throughout his career, Habjan has collaborated with notable colleagues, including Hubertus Hochrein and Henning Lauterbach. These partnerships have further enhanced his research and contributed to the advancement of cancer treatment methodologies.

Conclusion

Matthias Habjan's contributions to cancer treatment through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…